newsfilter
← Earnings
Earnings Releases·

Vaxart — Third Quarter 2026 Earnings Summary

  • Revenue declined 85% year-over-year to $10.6 million in Q3 2026 from $72.4 million in Q3 2025, while net loss widened to $17.7 million from $8.1 million; R&D expenses fell 70% to $22.8 million, offset by a rise in G&A to $5.1 million.
  • Cash and investments stood at $65.5 million as of September 30, 2026, with management projecting a cash runway extending into Q2 2027 while actively seeking non-dilutive funding and partnerships.
  • Topline efficacy and safety data from the Phase 2b COVID-19 trial are anticipated by mid-2027, supported by cumulative BARDA payments totaling $278.0 million.
  • Strategic developments include positive preclinical results for the H5N1 influenza candidate VXA-H5-02, a new European patent for norovirus technology extending protection to 2036, and the appointment of Vice Admiral Raquel C. Bono to the Board.
Company
VAXART INC
Sector
Healthcare
Industry
Biotechnology